Skip to main content
Genitourinary system

Genitourinary system

Search complete. 17 mentions across 8 episodes found for "Genitourinary system".

Oct 6, 2026

Gina BottaladoHOST
38:53
What do you do if the CT report simply says that there's an indeterminate adrenal nodule? What's your next move?
Benjamin RistauGUEST
39:00
So I, I really appreciate the radiology colleagues for, uh, non-GU organs.
Benjamin RistauGUEST
39:07
I think at this point I've looked at enough urologic radiology to put myself up there with most radiologists that I encounter.
Benjamin RistauGUEST
39:17
So I'm looking at all these images myself.
Neil LoveHOST
20:08
So let's start talking a little bit about more practical issues.
Neil LoveHOST
20:12
You know, one of the things, I don't know whether, you know, I never can tell, you know, we're dealing with people from GU, GI, breast, you know, heme.
Neil LoveHOST
20:20
And, you know, you kind of get different feelings from groups when new data comes out.
Neil LoveHOST
20:25
And I kind of remember that around the time that we started to see that the Capitella trial was positive, I think there might have been a press release in an ESMO last fall, the data was actually presented, you know, it's kind of hard to quantitate it.
Neil LoveHOST
20:39
And we did start quantitating it, actually.
Neil LoveHOST
20:42
But I kind of got the feeling that when this initially came out, there was a lot of hesitation in the GU community.
Neil LoveHOST
20:49
I think because of lack of experience with this therapy, you know, you have this, you know, hyperglycemia, rash, you hear about these things.
Neil LoveHOST
20:56
Although it is interesting, of course, you know, the four-day-on, three-day-off schedule is, you know, I think probably helpful in terms of toxicity.
Daphna Yasova BarbeauHOST
9:48
Okay, neonates with major congenital anomalies, I told you, were excluded.
Daphna Yasova BarbeauHOST
9:52
So they pulled out babies with abdominal wall defects, colboma, heart defects, atresias, growth retardation, GU anomalies, vertebral anomalies, and again, GI conditions such as neck were excluded because of the risk of systemic inflammation and infection.
Daphna Yasova BarbeauHOST
10:12
Okay.
Daphna Yasova BarbeauHOST
10:13
So among the cohort, 17.4%, around 307 infants, were considered to have a neurologic cause of death.
speaker_0NARRATOR
0:00
Welcome to The View on GU, the place to be for translating uro-oncology knowledge to action.
speaker_0NARRATOR
0:06
Here are your hosts, Doctors Ali Khan-Lalani and Christopher Wallace.
Christopher WallisHOST
0:10
[upbeat music] Hello, and welcome to The View on GU.
Christopher WallisHOST
0:17
I'm Chris Wallace, along with my co-host, Ali Khan-Lalani.
Christopher WallisHOST
0:20
Ali Khan, it's good to be back.
Alejandro BerlinGUEST
4:39
It's just faster, it's more convenient, it's cheaper for the system and for the patient, so those are good stuff to have, um, but it's equivalent.
Alejandro BerlinGUEST
4:48
So I don't think someone doing more moderate hypofractionation than SBRT is giving a substandard treatment.
Alejandro BerlinGUEST
4:56
That being said, obviously the convenience of doing it in five or seven fraction is there, at the expense of slightly more toxicity in GU particularly, and a little bit more risk of a treatment-related swelling, obstruction, needing of tamsulosin and those family of drugs, sometimes even steroids or anti-inflammatories.
Simone GonzoGUEST
7:06
So select them using current guidance and the patient's comorbidities and medicines.
Simone GonzoGUEST
7:12
Genitourinary symptoms require direct questioning because patients may not volunteer vaginal dryness, dyspareunia, urinary urgency or recurrent urinary symptoms.
Simone GonzoGUEST
7:24
Local vaginal estrogen can be considered the genitourinary syndrome of menopause, GSM, with individual assessment.
Simone GonzoGUEST
7:32
Lubricants and moisturizers can also help Mood and cognition deserve nuance.
Ray McDermottGUEST
22:52
I was vice clinical lead at Cancer Trials Ireland first, and I was clinical lead for two separate occasions.
Ray McDermottGUEST
22:59
And a lot of that is like moving it from being a breast cancer organization, which John set up basically to widening the, you know, the breadth of trials and getting trials in GU and making it into another diseases and making it into a proper organization which serves the whole country.
Ray McDermottGUEST
23:18
And I think.
Ray McDermottGUEST
23:19
You know, Seamus O'Reilly is now in charge and he's from Cork, which is great because, you know, it represents the whole country.
Shalini MoningiGUEST
1:01
So I am a radiation oncologist, and I work at Cleveland Clinic.
Shalini MoningiGUEST
1:06
A little bit about me, I specialize in GU cancers, do brachytherapy, um, as well as external beam therapy for prostate cancer.
Shalini MoningiGUEST
1:13
Um, I'm the section head for the GU program here at Cleveland Clinic, and a lot of my passion really is on quality of life outcomes for patients with prostate cancer and really, you know, how to improve their quality of life and outcomes in the long run.
Shalini MoningiGUEST
1:26
And so this paper is a really great example of some things that we're-- that I'm passionate about.
Manuj AgarwalHOST
1:31
Okay.

16 MINS LATER

Shalini MoningiGUEST
17:09
And it might be a little bit more for me because I'm a female, but I think in general, though, patients do sometimes don't wanna talk about it even though it does bother them quite a bit.
Manuj AgarwalHOST
17:18
Totally.
Shalini MoningiGUEST
17:18
And I think it is our-- like, it is our duty to bring it up because that is one huge quality-of-life impediment, right? Not just GU and GI issues, and I think it is our job to bring this up and make the patient feel comfortable so that we can talk about this.
RoryHOST
18:49
Because if you imagine you've done an abdo surgery, sealed up the abdo, and that wound just bursts open, really concerning.
RoryHOST
18:57
Genitourinary, JC?
JontyHOST
18:59
So again, thinking along the lines of infection.
JontyHOST
19:02
So this time we're talking about UTI.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.